Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Collegium Pharmaceutical Inc is a drug manufacturers-specialty & generic business based in the US. Collegium Pharmaceutical shares (COLL) are listed on the NASDAQ and all prices are listed in US Dollars. Collegium Pharmaceutical employs 234 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$21.35|
|52-week range||$17.24 - $26.91|
|50-day moving average||$20.26|
|200-day moving average||$22.12|
|Wall St. target price||$26.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.85|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||0.57%|
|1 month (2021-09-24)||4.45%|
|3 months (2021-07-26)||-13.25%|
|6 months (2021-04-26)||-8.17%|
|1 year (2020-10-23)||10.39%|
|2 years (2019-10-25)||69.44%|
|3 years (2018-10-25)||30.50%|
|5 years (2016-10-25)||26.56%|
Valuing Collegium Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Collegium Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Collegium Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Collegium Pharmaceutical shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Collegium Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $140.7 million.
The EBITDA is a measure of a Collegium Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$326.1 million|
|Operating margin TTM||22.15%|
|Gross profit TTM||$240.5 million|
|Return on assets TTM||6.64%|
|Return on equity TTM||52.22%|
|Market capitalisation||$749 million|
TTM: trailing 12 months
There are currently 3.7 million Collegium Pharmaceutical shares held short by investors – that's known as Collegium Pharmaceutical's "short interest". This figure is 2.5% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Collegium Pharmaceutical shares can be evaluated.
Collegium Pharmaceutical's "short interest ratio" (SIR) is the quantity of Collegium Pharmaceutical shares currently shorted divided by the average quantity of Collegium Pharmaceutical shares traded daily (recently around 249191.81208054). Collegium Pharmaceutical's SIR currently stands at 14.9. In other words for every 100,000 Collegium Pharmaceutical shares traded daily on the market, roughly 14900 shares are currently held short.
However Collegium Pharmaceutical's short interest can also be evaluated against the total number of Collegium Pharmaceutical shares, or, against the total number of tradable Collegium Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Collegium Pharmaceutical's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Collegium Pharmaceutical shares in existence, roughly 100 shares are currently held short) or 0.1532% of the tradable shares (for every 100,000 tradable Collegium Pharmaceutical shares, roughly 153 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Collegium Pharmaceutical.
Find out more about how you can short Collegium Pharmaceutical stock.
We're not expecting Collegium Pharmaceutical to pay a dividend over the next 12 months.
Over the last 12 months, Collegium Pharmaceutical's shares have ranged in value from as little as $17.24 up to $26.91. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Collegium Pharmaceutical's is 1.054. This would suggest that Collegium Pharmaceutical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Collegium Pharmaceutical, Inc. , a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.